<DOC>
	<DOCNO>NCT00544193</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose gemcitabine give together radiation therapy treat patient locally advanced upper gastrointestinal cancer .</brief_summary>
	<brief_title>Gemcitabine Radiation Therapy Treating Patients With Locally Advanced Upper Gastrointestinal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine feasibility combine preoperative intraoperative gemcitabine hydrochloride intraoperative radiotherapy . - To determine tolerance gemcitabine hydrochloride give concurrently external-beam radiotherapy . - To measure biochemical parameter tumor may correlate effectiveness therapy . OUTLINE : Patients receive gemcitabine hydrochloride IV 12-18 hour prior plan surgery . All patient undergo exploratory laparotomy may include tumor debulking , Whipple-type resection ( pancreaticoduodenectomy ) , total pancreatectomy , gastrojejunostomy , total partial gastrectomy , cholecystectomy en bloc resection depend extent disease . Patients metastatic disease beyond regional lymph node also undergo intraoperative radiotherapy . Beginning 2-6 week surgery , patient undergo external-beam radiotherapy ( EBRT ) day 5 day week 7 week . Patients also receive escalate dos gemcitabine hydrochloride IV begin week EBRT . Patients undergo tissue sample collection periodically correlative study . Samples analyze thymidylate synthase ( TS ) , ribonucleotide reductase ( RR ) , excision-repair-cross-complementing ( ERCC ) -1 protein , deoxycytidine kinase mRNA . Biopsy tissue also analyze gemcitabine triphosphate , dATP , dCTP content . p53 status assess via immunohistochemistry mRNA level via quantitative polymerase chain reaction ( PCR ) . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , year thereafter .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follow upper gastrointestinal malignancy : Localized pancreatic adenocarcinoma Stage I , II , III disease Parapancreatic node involvement locally recurrent disease allow Locally advance biliary , gallbladder , ampullary adenocarcinoma Stage II , III , locally recurrent disease Histologically confirm locally advanced gastric adenocarcinoma T3 , T4 , node positive OR locally recurrent disease Histologically confirm locally advanced duodenal cancer Stage II III disease Locally advance , unresectable cancer may include protocol appropriate intraoperative radiotherapy ( IORT ) Other histology may consider protocol except lymphoma , sarcoma , neuroendocrine tumor Patients evidence metastatic disease eligible significant local disease warrant surgery IORT PATIENT CHARACTERISTICS : Karnofsky performance status &gt; 60 % Life expectancy &gt; 4 month Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Serum creatinine &lt; 2.0 mg/dL ALT &lt; 3 x normal Bilirubin &lt; 2 x normal Must able give voluntary inform consent No severe intercurrent illness would make patient inappropriate laparotomy otherwise inappropriate treatment protocol Prior history malignancy allow PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy ( 6 week mitomycin C ) Prior gemcitabine hydrochloride allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>localize gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage I gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>